Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma. Academic Article uri icon

Overview

abstract

  • A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity. m-AMSA has little activity in patients with gastric adenocarcinoma.

publication date

  • June 1, 1982

Research

keywords

  • Adenocarcinoma
  • Aminoacridines
  • Antineoplastic Agents
  • Stomach Neoplasms

Identity

Scopus Document Identifier

  • 0020316214

Digital Object Identifier (DOI)

  • 10.1097/00000421-198206000-00006

PubMed ID

  • 6896259

Additional Document Info

volume

  • 5

issue

  • 3